John Henneman
Chairman at ANIKA THERAPEUTICS, INC.
Net worth: 2 M $ as of 2024-04-29
John Henneman active positions
| Companies | Position | Start | End |
|---|---|---|---|
| R1 RCM INC. | Director/Board Member | 2016-02-15 | - |
| Independent Dir/Board Member | 2016-02-15 | - | |
| APREA THERAPEUTICS, INC. | Director/Board Member | 2019-07-31 | - |
| Independent Dir/Board Member | 2019-07-31 | - | |
| ANIKA THERAPEUTICS, INC. | Independent Dir/Board Member | 2020-09-02 | - |
| Chairman | 2024-02-23 | - | |
| Director/Board Member | 2020-09-02 | 2024-02-23 | |
| ORTHOFIX MEDICAL INC. | Director/Board Member | 2023-01-04 | - |
| Independent Dir/Board Member | 2023-01-04 | - | |
Alafair Biosciences, Inc.
 Alafair Biosciences, Inc. Medical SpecialtiesHealth Technology Alafair Biosciences, Inc. operates as a medical device company. It develops novel suite of products based on a non-cell adhesive hydrogel technology that protects and manages advanced wound healing. The firm addresses problems of wound healing and scar prevention with natural, animal-free biopolymer based products that are biocompatible, bioresorbable and hydrate injured tissues throughout healing. The company was founded by Daniel L. Peterson, John D. Joyoprayitno and Sarah Mayes in 2011 and is headquartered in Austin, TX. | Director/Board Member | 2014-12-31 | - |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Director/Board Member | 2019-07-31 | - |
Career history of John Henneman
Former positions of John Henneman
| Companies | Position | Start | End |
|---|---|---|---|
| SEAE HLDG | Director/Board Member | 2015-06-30 | 2023-01-04 |
| Independent Dir/Board Member | 2015-06-30 | 2023-01-04 | |
| LUMOS PHARMA, INC. | Chief Administrative Officer | 2018-07-25 | 2018-10-31 |
| Director of Finance/CFO | 2014-09-30 | 2018-07-25 | |
| Corporate Secretary | 2014-08-31 | 2018-07-25 | |
| INTEGRA LIFESCIENCES HOLDINGS CORPORATION | Chief Administrative Officer | 1998-08-31 | 2006-12-31 |
| Director of Finance/CFO | 2006-12-31 | 2014-08-31 | |
| General Counsel | 1998-08-31 | 2006-12-31 | |
| ░░░░░░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░ | - | - |
| ░░░░░░░░░ ░░░░░░░░░ | - | - | |
| ░░░ ░░░░ ░░░░░░░░░░ ░░░ | ░░░░░░░░ | - | - |
Training of John Henneman
| Princeton University | Undergraduate Degree |
| The University of Michigan Law School | Graduate Degree |
Statistics
International
| United States | 12 |
| France | 2 |
| Sweden | 2 |
Operational
| Director/Board Member | 7 |
| Independent Dir/Board Member | 5 |
| Chief Administrative Officer | 2 |
Sectoral
| Health Technology | 10 |
| Consumer Services | 3 |
| Technology Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 5 |
|---|---|
| INTEGRA LIFESCIENCES HOLDINGS CORPORATION | Health Technology |
| R1 RCM INC. | Commercial Services |
| APREA THERAPEUTICS, INC. | Health Technology |
| ANIKA THERAPEUTICS, INC. | Health Technology |
| ORTHOFIX MEDICAL INC. | Health Technology |
| Private companies | 6 |
|---|---|
New Deal Technology SAS
 New Deal Technology SAS Medical SpecialtiesHealth Technology New Deal Technology SAS develops and manufactures specialty implants and instruments for foot and ankle surgery. It offers adjustment guides, ankle prosthesis, fracture plates, compression pins, compression screws, compression staples and flat foot implants. The company was founded in 1997 by Fourcault Eric and is headquartered in Lyon, France. | Health Technology |
| Neuromedical Systems, Inc. | Health Technology |
NewLink Genetics Corp.
 NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA. | Health Technology |
SeaSpine Holdings Corp.
 SeaSpine Holdings Corp. Information Technology ServicesTechnology Services SeaSpine Holdings Corp. operates as a medical technology company. The firm engages in the design, developmen and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. It products include thoracolumbar hardware, cervical hardware, orthobiologics, and spine pure strip. The company was founded on February 12, 2015 and is headquartered in Carlsbad, CA. | Technology Services |
Alafair Biosciences, Inc.
Alafair Biosciences, Inc. Medical SpecialtiesHealth Technology Alafair Biosciences, Inc. operates as a medical device company. It develops novel suite of products based on a non-cell adhesive hydrogel technology that protects and manages advanced wound healing. The firm addresses problems of wound healing and scar prevention with natural, animal-free biopolymer based products that are biocompatible, bioresorbable and hydrate injured tissues throughout healing. The company was founded by Daniel L. Peterson, John D. Joyoprayitno and Sarah Mayes in 2011 and is headquartered in Austin, TX. | Health Technology |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
- Stock Market
- Insiders
- John Henneman
- Experience
